Dovprela (previously Pretomanid FGK)



This medicine is authorised for use in the European Union.


Pretomanid FGK is a medicine for treating adults with drug-resistant tuberculosis. It is used to treat tuberculosis that is:

  • extensively drug-resistant (resistant to at least 4 antibiotics used for treating tuberculosis, including the standard antibiotics isoniazid and rifampicin);
  • multi-drug resistant (resistant to isoniazid and rifampicin) and when antibiotics used for this form of tuberculosis do not work or cause unacceptable side effects.

Pretomanid FGK is used together with bedaquiline and linezolid.

Pretomanid FGK contains the active substance pretomanid.

Tuberculosis is rare in the EU, and Pretomanid FGK was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 29 November 2007.

This EPAR was last updated on 24/02/2023

Authorisation details

Product details
Dovprela (previously Pretomanid FGK)
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Tuberculosis, Multidrug-Resistant
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Conditional approvalConditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation.


This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Mylan Ireland Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Unit 35/36 Grange Parade
Baldoyle Industrial Estate
Dublin 13

Product information

22/02/2023 Dovprela (previously Pretomanid FGK) - EMEA/H/C/005167 - IB/0014/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Assessment history

Related content

How useful was this page?

Add your rating
2 ratings
2 ratings
5 ratings
1 rating